

# Supplementary Material

## COVID-19 Case Fatality and Alzheimer's Disease

**Supplementary Table 1.** Baseline characteristics of patients with COVID-19 in the TriNetX research network as of February 17, 2021.

<b>Characteristics</b>	<b>All participants (n = 387,841)</b>	<b>Deceased (n = 13,458)</b>	<b>Alive (n = 374,383)</b>
Age, median (IQR), y	51 (35–65)	74 (63-83)	50 (34-64)
<50	186,832 (48.2)	1,043 (7.8)	185,789 (49.6)
50–59	67,647 (17.4)	1,393 (10.4)	66,254 (17.1)
60–69	61,557 (15.9)	2,769 (20.6)	58,788 (15.7)
70–79	42,056 (10.8)	3,647 (27.1)	38,409 (10.3)
>80	29,749 (7.7)	4,606 (34.2)	25,143 (6.7)
<b>Sex</b>			
Female	215,054 (55.4)	5,748 (42.7)	209,306 (55.9)
Male	172,787 (44.6)	7,710 (57.3)	165,077 (44.1)
<b>Race</b>			
White	235,543 (60.7)	7,874 (58.5)	227,669 (60.8)
Black or African American	66,544 (17.2)	2,790 (20.7)	63,754 (17.0)
Other	85,754 (22.1)	2,794 (20.8)	82,960 (22.2)
<b>Ethnicity</b>			
Non-Hispanic	232,979 (60.1)	8,547 (63.5)	224,432 (59.9)
Hispanic	48,331 (12.5)	1196 (8.9)	47,135 (12.6)
Unknown	106,531 (27.5)	3,715 (27.6)	102,816 (27.5)
<b>Dementia disorders</b>			
Alzheimer's disease	4,174 (1.1)	754 (5.6)	3,420 (0.9)
Vascular dementia	2,765 (0.7)	491 (3.6)	2,274 (0.6)
Dementia with Lewy bodies	375 (0.1)	71 (0.5)	304 (0.1)
Frontotemporal dementia	235 (0.1)	40 (0.3)	195 (0.1)
<b>Elixhauser comorbidity index</b>			
0	130,266 (33.6)	746 (5.5)	129,520 (34.6)
1-4	165,751 (42.7)	3,320 (24.7)	162,431 (43.4)
5 or above	91,824 (23.7)	9,392 (69.8)	82,432 (22.0)

<b>Comorbidities within the Elixhauser comorbidity index</b>			
Congestive heart failure	33,066 (8.5)	4,813 (35.8)	28,253 (7.5)
cardiac arrhythmias	87,339 (22.5)	8,292 (61.6)	79,047 (21.1)
valvular disease	32,603 (8.4)	3,646 (27.1)	28,957 (7.7)
pulmonary circulation disorders	18,295 (4.7)	2,492 (18.5)	15,803 (4.2)
peripheral vascular disorders	31,371 (8.1)	3,800 (28.2)	27,571 (7.4)
hypertension, uncomplicated	136,683 (35.2)	8,761 (65.1)	127,922 (34.2)
hypertension, complicated	36,644 (9.4)	5,005 (37.2)	31,639 (8.5)
Paralysis	5,751 (1.5)	708 (5.3)	5,043 (1.3)
other neurological disorders	348,22 (9.0)	5,242 (39.0)	29,580 (7.9)
chronic pulmonary disease	77,289 (19.9)	4,481 (33.3)	72,808 (19.4)
diabetes, uncomplicated	64,655 (16.7)	4,662 (34.6)	59,993 (16.0)
diabetes, complicated	49,699 (12.8)	4,839 (36.0)	44,860 (12.0)
Hypothyroidism	41,462 (10.7)	2,545 (18.9)	38,917 (10.4)
renal failure	35,167 (9.1)	5,055 (37.6)	30,112 (8.0)
liver disease	30,432 (7.8)	2,439 (18.1)	27,993 (7.5)
peptic ulcer disease, excluding bleeding	5,514 (1.4)	461 (3.4)	5,053 (1.3)
AIDS/HIV	2,194 (0.6)	73 (0.5)	2,121 (0.6)
Lymphoma	3,403 (0.9)	392 (2.9)	3,011 (0.8)
metastatic cancer	6,566 (1.7)	831 (6.2)	5,735 (1.5)
solid tumor, without metastasis	23,431 (6.0)	1,971 (14.6)	21,460 (5.7)
rheumatoid arthritis/collagen vascular disease	18,018 (4.6)	1,020 (7.6)	16,998 (4.5)
Coagulopathy	24,407 (6.3)	4,046 (30.1)	20,361 (5.4)
Obesity	82,289 (21.2)	4,038 (30.0)	78,251 (20.9)
weight loss	22,345 (5.8)	3,049 (22.7)	19,296 (5.2)
fluid and electrolyte disorders	80,362 (20.7)	9,121 (67.8)	71,241 (19.0)
blood loss anemia	7,635 (2.0)	670 (5.0)	6,965 (1.9)
deficiency anemia	25,887 (6.7)	2,109 (15.7)	23,778 (6.4)
alcohol abuse	11,952 (3.1)	749 (5.6)	11,203 (3.0)
drug abuse	15,031 (3.9)	666 (4.9)	14,365 (3.8)
Psychoses	5,753 (1.5)	459 (3.4)	5,294 (1.4)
Depression	68,731 (17.7)	3,191 (23.7)	65,540 (17.5)

Results are n (%) unless otherwise stated.

COVID-19, coronavirus disease 2019; IQR, interquartile range